LONDON--(BUSINESS WIRE)--Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced ...

CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among polycythemia vera patients who had been dependent on it, the ...

There is currently no cure for polycythemia vera (PV), but researchers are looking at new treatments that may help better manage and control the progression of the condition. Polycythemia vera (PV) is ...

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TPEx: 6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in ...

NEWARK, Calif., Dec. 12, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today presented updated data from two ongoing Phase 2 studies evaluating ...

A breakthrough in the treatment of polycythemia vera, a rare and life-threatening blood cancer, has emerged with the introduction of a new drug named rusfertide. Polycythemia vera falls under the ...

Findings showed 77% of PV patients treated with rusfertide achieved a clinical response compared with 33% of those who received placebo. Topline data were announced from a phase 3 trial evaluating ...

Besremi is a monopegylated, long-acting interferon, which exhibits its cellular effects in the bone marrow in polycythemia vera. The Food and Drug Administration (FDA) has approved Besremi ® ...

The Key Polycythemia Vera Companies in the market include - Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Protagonist ...

Polycythemia vera (PV) is a rare blood cancer causing the bone marrow to make too many blood cells. Treatment usually starts with phlebotomy and may continue with medications. If one treatment isn’t ...

Ono Pharmaceutical Co. Ltd. struck a licensing deal with Ionis Pharmaceuticals Inc. for sapablursen, which is in phase II trials for polycythemia vera. Under terms, Osaka, Japan-based Ono gains an ...